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Abstract
Lymphatic malformations (LMs) are vascular anomalies thought to arise from dysregulated
lymphangiogenesis. These lesions impose a significant burden of disease on affected indi-
viduals. LM pathobiology is poorly understood, hindering the development of effective treat-
ments. In the present studies, immunostaining of LM tissues revealed that endothelial cells
lining aberrant lymphatic vessels and cells in the surrounding stroma expressed the stem
cell marker, CD133, and the lymphatic endothelial protein, podoplanin. Isolated patient-
derived CD133+ LM cells expressed stem cell genes (NANOG, Oct4), circulating endotheli-
al cell precursor proteins (CD90, CD146, c-Kit, VEGFR-2), and lymphatic endothelial pro-
teins (podoplanin, VEGFR-3). Consistent with a progenitor cell identity, CD133+ LM cells
were multipotent and could be differentiated into fat, bone, smooth muscle, and lymphatic
endothelial cells in vitro. CD133+ cells were compared to CD133− cells isolated from LM flu-
ids. CD133− LM cells had lower expression of stem cell genes, but expressed circulating
endothelial precursor proteins and high levels of lymphatic endothelial proteins,
VE-cadherin, CD31, podoplanin, VEGFR-3 and Prox1. CD133− LM cells were not multipo-
tent, consistent with a differentiated lymphatic endothelial cell phenotype. In a mouse xeno-
graft model, CD133+ LM cells differentiated into lymphatic endothelial cells that formed
irregularly dilated lymphatic channels, phenocopying human LMs. In vivo, CD133+ LM cells
acquired expression of differentiated lymphatic endothelial cell proteins, podoplanin,
LYVE1, Prox1, and VEGFR-3, comparable to expression found in LM patient tissues.
Taken together, these data identify a novel LM progenitor cell population that differentiates
to form the abnormal lymphatic structures characteristic of these lesions, recapitulating the
human LM phenotype. This LM progenitor cell population may contribute to the clinically re-
fractory behavior of LMs.
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Introduction
Vascular anomalies are a heterogeneous group of lesions with arterial, venous, or lymphatic
components that develop in utero or shortly after birth. These lesions are classified into malfor-
mations and tumors, based on histological classification, endothelial cell morphology, and clin-
ical behavior [1–3]. Vascular malformations are further classified based on the cellular subtype
of the malformation, with lymphatic malformations (LMs) consisting of abnormal lymphatic
vasculature. LMs are subdivided on the basis of morphology, and include macrocystic (lumen
>1cm), microcystic (lumen<1cm), mixed macrocystic and microcystic (mixed), and diffuse
LMs (referred to as generalized lymphatic anomalies, GLA) [2–4].
The lymphatic vasculature functions in maintenance of interstitial fluid balance, mounting
immune responses, and uptake of lipids and lipid-soluble nutrients from the intestines. Conse-
quently, individuals with LMs are subject to significant morbidities resulting from disruption
of these essential functions, including lymphedema, lymphatic fluid pooling (chylous ascites
and chylothorax), and intralesional bleeding. Mass effects of large LMs can impair vital func-
tions, such as cervicofacial lesions that cause airway obstruction or impingement on the eye.
Superinfection of tissues in which lymphatic flow is impaired can lead to overwhelming sepsis.
Despite this significant burden of disease, the pathobiology of these lesions is
poorly understood.
LMs are frequently refractory to treatment. Often LMs cannot be removed in their entirety
by surgery, because they infiltrate normal tissues. Ablation by sclerotherapy is limited to
macrocystic areas. Thus, recurrence is common: 22–26% after surgery and 57% after sclero-
therapy [5, 6]. Lymphatic anomalies have been associated with mutations in VEGFR-3 (Mil-
roy’s disease), RASA1 (Capillary lymphatic-arteriovenous malformations, CLAVM), Foxc2
(Lymphedema-Distichiasis syndrome) and PTPN11 (Noonan’s syndrome) [7–10]. However,
the molecular causes of the majority of LMs remain unknown, hindering development of bio-
logically-targeted therapies.
Here, we identify a previously undescribed lymphatic malformation progenitor cell (LMPC)
population in LMs that line the aberrant lymphatic vessels and reside in adjacent parenchyma
in patient tissues. In LM tissues, LMPCs co-expressed the stem cell marker, CD133, and the
lymphatic endothelial cell (LEC) marker, podoplanin. CD133+ cells isolated from LM patient
tissues and fluid aspirates were multipotent, and expressed markers of stem cells, circulating
endothelial precursor cells, and LECs. We compared CD133+ LM cells to CD133− LM cells iso-
lated from LM fluids. Relative to CD133+ LM cells, CD133− LM cells had significantly lower
expression of stem cell markers, maintained expression of circulating endothelial precursor
markers, and expressed increased levels of differentiated LEC markers. Unlike CD133+ LM
cells, CD133− LM cells were not multipotent, suggesting that CD133− LM cells represent differ-
entiated lymphatic malformation endothelial cells (LMECs). We demonstrate that LMPCs re-
capitulate the LM phenotype in a mouse model. When xenografted in mice, CD133+ LM cells
differentiated into LECs that formed aberrant lymphatic vessels, morphologically and histolog-
ically similar to those observed in LM patient tissues. Taken together, these data suggest a pro-
genitor cell origin for human LMs.
Materials and Methods
Clinical Samples
Resected tissues and aspirated fluids were acquired from pediatric LM patients (infants to
adolescents). For histologic and molecular characterization, tissues were fixed in 4% paraformal-
dehyde, incubated in 20% sucrose/PBS, and frozen in OCT or fixed in formalin and paraffin-
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embedded. Cells were isolated immediately from resected tissues and aspirated fluids. Descrip-
tion of LM specimens and methodologies performed are presented in Table S1 in S1 File.
Cell Culture
LM cells were isolated from tissues or centrifuged fluids using the anti-CD133 bead selection
system (Miltenyi Biotec) as described [11, 12]. Cells were maintained in EGM-2 media (Lonza)
supplemented with 18% FBS on fibronectin-coated plates. Fluorescence-activated cell sorting
(FACS) of CD133+ live cells was performed to generate CD34-positive or negative populations,
and podoplanin-positive or negative populations. Hemangioma stem cells (HemSC) and
human dermal lymphatic endothelial cells (HdLECs) were isolated and maintained as de-
scribed [11–13]. Human bone marrow-derived mesenchymal stem cells (MSCs) were pur-
chased and maintained as described by the manufacturer (Lonza).
For differentiation assays, cells were plated at 50% confluency on fibronectin-coated wells
and grown in differentiation media for 14 days. Adipocyte differentiation media consisted of
1μg/ml insulin, 1μM dexamethasone, 0.5mM isobutylmethylxanthine, and 60μM indometha-
cin in 10%FBS/DMEM (low glucose) containing 1x penicillin-streptomycin. Adipogenesis was
confirmed by Oil Red O staining. Osteoblast differentiation media consisted of 60μM ascorbic
acid-2-phosphate, 10mM β̃glycerophosphate, and 1μM dexamethasone in 10%FBS/DMEM
containing 1x penicillin-streptomycin. Osteogenesis was determined by alkaline phosphatase
reaction. Mural cell differentiation media consisted of 10ng/ml TGFβ1 in 10% FBS/DMEM
containing 1x penicillin-streptomycin. Mural cell differentiation was determined by α̃smooth
muscle actin staining (Table S2 in S1 File). LEC differentiation media consisted of 10ng/ml
VEGF-B, 10ng/ml VEGF-C, 10μl/ml insulin-transferrin-selenium, 10μl/50ml linoleic acid-
albumin, 1nM dexamathasone, 60μM ascorbic acid-2-phosphate in EBM-2 (Lonza) containing
1x penicillin-streptomycin [14]. LEC differentiation was determined by CD31, VE-cadherin,
LYVE1, and podoplanin immunostaining and by qRT-PCR.
Immunohistochemistry (IHC)
Frozen and paraffin-embedded sections were immunostained as described [15, 16]. Cultured
cells were fixed in 4% paraformaldehyde and stained as described [11]. Primary antibodies in-
cluded α-smooth muscle actin (αSMA), CD133, CD31, GFP, LYVE1, NG2, Prox1, VE-cad-
herin, and VEGFR-3 (described in Table S2 in S1 File) and were detected with secondary Alexa
Fluor antibodies (Invitrogen). Mouse-on-mouse kit (Vector Labs) was used with mouse mono-
clonal antibodies in murine LM implants. Images were captured with a Nikon Eclipse E800 mi-
croscope and Nikon DXM 1200 digital camera, using ImagePro Plus v.4.01 software, or a Zeiss
Axioskop2 Plus and Zeiss AxioCamMRc camera with Zeiss Zen software.
Quantitative RT-PCR (qPCR)
RNA was isolated (RNeasy Mini Kit, Qiagen) and cDNA synthesized (SuperScript First-Strand
Synthesis System, Invitrogen) [17]. qPCR with Sybr Green Master Mix (ABI) was performed in
triplicates using a CFX96 PCR Cycler (Bio-rad). Gene-specific PCR products cloned into
pDrive (Stratagene) served as standards and reactions were normalized to β-actin. Primers are
listed in Table S3 in S1 File.
Fluorescence-activated cell sorting (FACS)
FACS antibodies included CD11b, CD146, CD31, CD34, CD90, podoplanin, VE-cadherin,
VEGFR-2, and VEGFR-3 (described in Table S2 in S1 File). After antibody incubation, cells
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were disaggregated through a cell strainer to generate a single cell suspension. FACS was per-
formed using FACSCalibur and CellQuestPro acquisition software (BD Biosciences) and the
BD FACSCalibur flow cytometer and Cellquest Pro software. For live cell sorting, 2.5 x 107
CD133+ LM cells were incubated with an antibody against CD34 or podoplanin (described in
Table S2 in S1 File), single cell suspensions generated, and single cells sorted using BD FAC-
SAria Cell Sorter (n = 3 CD133+ LM populations).
Mice
Immunocompromised C57Bl Rag2-/-;IL-2γC-/-;CBPeGFP/+ were generated by crossing CBPeGFP/
+ mice (Jackson Labs) with Rag2-/-;IL-2γC-/- mice (Taconic). LMPCs (1.5x106 or 3x106 cells)
were resuspended in 200μl or 400μL Matrigel Matrix Phenol Red-Free (BD) and injected into
the flanks of C57Bl Rag2-/-;IL-2γC-/-;CBPeGFP/+ mice or Nude (Nu/J) mice (n = 6 for each
LMPC population). Control mice received MSCs, HemSCs, HdLECs, or Matrigel alone (n =
5–8). Mice were sacrificed at 3 and 5 weeks, and the implants harvested and paraffin-
embedded.
Ethics Statement
For human studies, de-identified tissues and aspirated fluid were collected from discarded sur-
gical specimens. As protected health information (PHI) was neither stored nor disclosed to the
researchers, this study was deemed exempt by Columbia University IRB (AAAA7338). There-
fore, there was no verbal or written consent required. Mouse studies were approved by Colum-
bia University IACUC (AC-AAAC1609 and AC-AAAG5852).
Results
LM tissues contain CD133+ stromal and lymphatic endothelial cells
Involved and uninvolved tissues resected from a patient with a mixed cervicofacial LM were
stained for LEC markers, podoplanin and LYVE1. In uninvolved tissues, morphologically nor-
mal lymphatic vessels stained strongly for LYVE1 and podoplanin (Fig. 1A). In LM tissues,
cells lining the irregularly dilated or ectatic lymphatic channels stained weakly for LYVE1 and
strongly for podoplanin (Fig. 1A, Fig. IA in S2 File). In the LM tissue parenchyma, stromal
cells stained weakly for podoplanin. These podoplanin+ stromal cells had a mesenchymal mor-
phology, potentially consistent with that of an LM progenitor cell.
Circulating endothelial precursor cells have been shown to express CD133 [18, 19]. We de-
termined CD133 and podoplanin expression in LM tissues from 7 patients, as well as in control
neonatal foreskin (postnatal day 1), and 3 patient-matched uninvolved tissues. In neonatal
foreskin, lymphatic vessels expressed CD133 consistent with the lymphatic vessel immaturity
and active remodeling proposed to occur shortly after birth (Fig. 1B, Figs. IA, IB in S2 File)
[20]. In contrast, CD133 expression was very low in the mature lymphatic vessels in the unin-
volved tissue (Fig. 1B). The ectatic lymphatic endothelium and the cells lining the lymphatic
channels in LMs expressed both CD133 and podoplanin (Fig. 1B). In the parenchyma, two dif-
ferent sub-populations of CD133+ cells were observed, CD133+/podoplaninlow and CD133+/
podoplanin− cells. Parenchymal CD133+ cells were detected in all LM tissues evaluated (mixed
cervicofacial LM (n = 2), macrocystic subcutaneous LMs (under the skin; n = 2), macrocystic
mesenteric LM (n = 1), Gorham’s LM (n = 1), generalized lymphatic anomalies (GLA; n = 1)
(Fig. 1B, data not shown). CD133 expression in the lymphatic endothelium in LMs was similar
to the immature neonatal lymphatic vasculature, suggesting arrested or defective development
of LM lymphatics. In contrast, CD133 expression was only weakly expressed in normal LECs,
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Fig 1. Identification of CD133+ cells in LMs of different subtypes and anatomical locations. (A) LYVE1
and podoplanin staining of cervicofacial mixed LM tissue and patient-matched uninvolved tissue. White
arrowheads mark normal lymphatics. (B) Podoplanin and CD133 staining of neonatal foreskin (postnatal day
1), uninvolved tissue, mixed cervicofacial (Mixed CF) LM tissues (2x), and Gorham’s dermal tissue. White
arrowheads mark CD133+/podoplanin+ lymphatic endothelium. Red arrowheads mark CD133low/podoplanin+
lymphatic endothelium. Yellow arrowheads mark CD133+/podoplanin+ stromal cells. Blue asterisks mark
blood vessels with autofluorescing red blood cells. Scale bars: 50μm. lymphatic channel (lc)
doi:10.1371/journal.pone.0117352.g001
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consistent with their mature status. CD133+/podoplanin+ cells were observed in several differ-
ent subtypes of LMs from various anatomic locations. Despite this anatomic and subtype het-
erogeneity, our data indicates that these CD133+/podoplanin+ LM cells are common to
multiple lymphatic anomalies.
CD133+ LM cells express markers of stem cells and endothelial cell
precursors
CD133+ cells were isolated from resected LM tissues and fluids, and compared to CD133-
negative (CD133−) cells isolated from LM fluids. LMs specimens included cervicofacial (CF)
LMs, mesenteric (Mes) LMs, subcutaneous (SC) LMs and GLAs. Patient-matched CD133+ and
CD133− LM cell populations were screened for the expression of markers of bone marrow and
circulating endothelial precursors (CD34, CD90, CD146 and VEGFR-2), and for lymphatic en-
dothelial markers (podoplanin and VEGFR-3) [14, 21]. Both CD133+ and CD133− LM cells ex-
pressed CD34, CD90, and VEGFR-2 (Fig. 2). CD133+ LM cells also expressed CD146,
podoplanin, and VEGFR-3, and their expression was often increased in the patient-matched
CD133− LM cells.
In murine inflammatory and tumor lymphangiogenesis, a subset of LECs has been sug-
gested to arise from a myeloid/monocyte cell [14, 22, 23]. The expression of the myeloid mark-
er, CD45, and the monocyte marker, CD11b, was assessed in CD133+ and CD133− LM cells.
CD11b expression was absent or low in a majority of the podoplanin+ cells, irrespective of their
CD133 status (Fig. IIA in S2 File). CD45 expression was not observed (data not shown).
We assessed transcript expression of the stem cell markers, Oct4, NANOG and Sox2, as well
as the endothelial precursor marker, c-Kit. Expression of c-Kit, Oct4, and NANOG was de-
tected in CD133+ LM cells, and significantly lower or absent in CD133− LM cells (Fig. IIB in
S2 File). Sox2 was not expressed in either LM cell population (data not shown).
In summary, CD133+ cells isolated from LM patient samples expressed markers of endothe-
lial precursors (CD34, CD90, CD146, VEGFR-2) and LECs (podoplanin, VEGFR-3), as well as
stem cells. As compared to CD133+ cells, CD133− LM cells had similar expression levels of en-
dothelial precursor markers (CD90, CD146, VEGFR-2), but had increased expression of the
lymphatic endothelial specific markers, (podoplanin, VEGFR-3) and lower expression of stem
cell genes. Thus, CD133+ and CD133− cells isolated from LM specimens are related, but dis-
tinct. CD133+ LM cells were more progenitor-like, while CD133− LM cells were similar to ma-
ture LECs.
CD133− LM cells exhibit features consistent with lymphatic endothelial
cells
CD133− cells isolated from fluids collected from 15 LM patients (cervicofacial LMs (n = 4),
mesenteric LMs (n = 4), thoracic LM (n = 1), subcutaneous LMs (n = 4) and GLA (n = 2)) were
compared to CD133+ LM cells and neonatal human dermal lymphatic endothelial cells
(HdLEC; n = 3). Expression of endothelial (VE-cadherin, VEGFR-2) and lymphatic endothelial
(podoplanin, VEGFR-3, Prox1, LYVE1) gene transcripts was determined (Fig. 3A). As com-
pared to CD133+ LM cells that expressed low levels of endothelial and LEC genes, a majority of
CD133− LM cells expressed higher levels of VE-cadherin, VEGFR-2, VEGFR-3, and Prox1.
Podoplanin, Prox1 and VEGFR-3 expression levels were often higher than that those observed
for HdLECs. In contrast, CD133− LM cells expressed lower levels of LYVE1 than HdLECs.
Two of the CD133− LM cell populations, one isolated from a microcystic mesenteric LM and
the other isolated from a GLA specimen, only expressed podoplanin similar to HdLECs,
whereas VEGFR-2, VEGFR-3, Prox1 and LYVE1 expression was more similar to that of
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Fig 2. Endothelial precursor and lymphatic endothelial protein expression in isolated CD133+ and CD133− LM cells. FACS of patient-matched
CD133+ and CD133− LM cells isolated frommicrocystic mesenteric (Micro Mes) LM, microcystic subcutaneous (Micro SC) LM and general lymphatic
anomaly (GLA) specimens. (A) Endothelial precursor markers, CD34, CD90, CD146 and VEGFR-2. (B) Lymphatic endothelial cell markers, podoplanin and
VEGFR-3. Blue line represents antibody data, and red line IgG control.
doi:10.1371/journal.pone.0117352.g002
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Fig 3. Expression of markers for mature lymphatic endothelial cells in isolated CD133+ and CD133−
LM cells. (A) Podoplanin, VE-cadherin, VEGFR-2, VEGFR-3, Prox1, and LYVE1 qRT-PCR of RNA isolated
from CD133+ and CD133− cells from LMs of different subtypes and anatomical locations and GLA compared
to control HdLECs. Data normalized to β-actin qRT-PCR and represented as mean ± s.e.m. (B) CD31 and
VE-cadherin FACS of patient-matched CD133+ and CD133− LM cells isolated frommicrocystic mesenteric
(Micro Mes) LM, microcystic subcutaneous (Micro SC) LM and general lymphatic anomaly (GLA) specimens.
Thick gray line represents antibody data, and black line IgG control. (C) VE-cadherin/CD31 and (D)
podoplanin/LYVE1 staining of patient-matched CD133+ and CD133− LM cells isolated frommicrocystic
mesenteric (Micro Mes) LM, microcystic subcutaneous (Micro SC) LM, and GLA compared to control HdLEC.
Scale bars: 50μm.
doi:10.1371/journal.pone.0117352.g003
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CD133+ LM cells. This expression pattern is consistent with these two CD133− LM cell popula-
tions being relatively less differentiated.
FACS and immunostaining were performed on patient-matched CD133+ and CD133− LM
cells to assess expression of the mature endothelial markers, VE-cadherin and CD31. All
CD133− LM cells expressed CD31, where as its expression was inconsistently observed in
CD133+ LM cells (Fig. 3B, 3C). Although VE-cadherin expression was observed in majority of
CD133− LM cells by immunostaining, its expression was poorly localized to adherens junctions
as compared to HdLECs (Figs. 3C bottom panels). Consistent with the immunostaining of the
CD133− LM cells isolated from a GLA, FACS for VE-cadherin did not detect cell surface ex-
pression (Figs. 3B, 3C).
Patient-matched CD133+ and CD133− LM cells were immunostained for the lymphatic en-
dothelial markers, LYVE1 and podoplanin. Expression of podoplanin was higher in
CD133− LM cells relative to CD133+ LM cells (Fig. 3D). When compared to HdLECs,
CD133− LM cells expressed lower levels of LYVE1 and higher levels of podoplanin (Fig. 3D),
similar to the abnormal lymphatic endothelium in LM tissues (Fig. 1A) and the transcriptional
analyses (Fig. 3A).
Overall, expression of LEC genes was lower in CD133+ LM cells relative to CD133− cells,
whereas CD133− LMs were more similar to HdLECs. Based on our assessment of markers, we
designated CD133+ LM cells as lymphatic malformation progenitor cells (LMPCs), and
CD133− LM cells as lymphatic malformation endothelial cells (LMECs).
LMPCs are multipotent and can be induced to differentiate down multiple
lineages
We hypothesized that LMPCs are progenitor-like and predicted that they would be multipo-
tent. We thus assessed the ability of CD133+ LMPCs to be induced down multiple cell lineages.
5 LMPC populations and 3 LMEC populations were cultured in induction media for adipo-
cytes, osteoblasts, and vascular smooth muscle cells (VSMCs). After two weeks in adipogenic
medium, LMPCs, but not LMECs, differentiated into adipocytes as assessed by Oil Red O stain-
ing for lipid accumulation (Fig. 4A, Fig. IIIA in S2 File). Similarly, only LMPCs differentiated
into osteoblasts, as demonstrated by the presence of alkaline phosphatase activity (Fig. 4B,
Fig. IIIB in S2 File). LMPC adipogenesis and osteogenesis was similar to that observed for
human MSCs (Fig. III in S2 File).
LMPCs cultured in mural cell differentiation media for two weeks expressed alpha smooth
muscle cell actin (αSMA), consistent with VSMC differentiation (Fig. 4C). LMPCs maintained
in growth medium expressed higher levels of the pericyte marker, NG2, than those in the
mural cell differentiation media (Fig. 4C). We assessed whether NG2 expression was observed
in LM tissues and found that CD133+ cells co-expressed NG2 (Fig. IVA in S2 File). Cultured
CD133+ LMPC populations expressed NG2, while NG2 expression was lower in patient-
matched CD133− LMECs (Figs. IVB, S4C in S2 File). Thus, NG2 appears to be a marker of
LMPCs and its expression was lower in LMECs relative to LMPCs.
FACS analyses indicated that LMPCs are a heterogeneous population of cells (Fig. 2). To de-
termine if CD34+ or podoplanin+ LMPCs are multipotent, three early passage LMPC popula-
tions were live cell sorted for CD34 and podoplanin, and positive and negative populations
collected. Sorted LMPCs were cultured in adipogenic, osteogenic and mural cell differentiation
media for 2 weeks and cell differentiation assessed. CD34+ and podoplanin+ LMPCs differenti-
ated into fat, bone and VSMCs (Figs. VA-C in S2 File). CD34− or podoplanin− cells from two
LMPC populations failed to expand after FACS. CD34− or podoplanin− cells isolated from a
subcutaneous LM did differentiate down the bone pathway, but poorly differentiated down fat
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or VSMC pathways (data not shown). Thus, multipotency was observed in the CD34+ and
podoplanin+ LMPC populations.
LMPCs differentiate into LMECs in vitro
To determine if LMPCs could differentiate into LMECs, we cultured five LMPC populations
and three CD34+ or podoplanin+ LMPC populations in LEC differentiation media. After two
weeks, LMPCs strongly expressed VE-cadherin and podoplanin, while CD31 and LYVE1 ex-
pression were modestly upregulated (Figs. 5A, 5B; Fig. VD in S2 File). In contrast, expression
of all four endothelial and lymphatic endothelial proteins was low in LMPCs maintained in
growth media. In LMPCs grown in LEC differentiation media, VE-cadherin was cytoplasmic
and not localized to the adherens junctions, and LYVE1 was poorly expressed, similar to
LMECs (Figs. 3C, 5A, 5B). In all LMPCs induced down the LEC fate, podoplanin and VEGFR-
2 transcripts were significantly upregulated, but LYVE1 was not induced (Fig. 5C). Similar to
the heterogeneity observed in the different LMEC populations, LEC markers, VE-cadherin,
Prox1, and VEGFR-3 were only upregulated in a subset of the LMPCs in differentiation media.
Although not normally expressed by LECs, the blood endothelial cell-specific VEGFR-1 was
Fig 4. Differentiation of LMPCs into fat, bone and smoothmuscle cells. (A) Oil Red O staining of LMPCs isolated frommacrocystic cervicofacial (Macro
CF) LM and microcystic mesenteric (Micro Mes) LM after 2 weeks in growth media (control) or adipogenic media. (B) Alkaline phosphatase (Alk Phos)
staining of LMPCs isolated frommacrocystic Macro CF LM and Micro Mes LM after 2 weeks in growth media (control) or osteogenic media. (C) NG2 and
alpha smooth muscle actin (αSMA) staining of LMPCs isolated fromMicro Mes LM after 2 weeks in growth media (control) or mural cell differentiation (Diff)
media. Scale bars: 50μm.
doi:10.1371/journal.pone.0117352.g004
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increased in two of the LMPCs induced down the lymphatic endothelial pathway. LMPCs dif-
ferentiated into LECs that appear similar to CD133− LMECs isolated from patients.
LMPCs recapitulate the LM phenotype in mice
To determine whether isolated LMPCs have the capacity to form lesions in vivo that pheno-
copy human LMs, six CD133+ LMPC populations isolated from cervicofacial (CF, n = 2),
mesenteric (Mes, n = 2), and subcutaneous (SC, n = 1) LMs, and a GLA were suspended in
Matrigel and implanted into GFP-expressing immunocompromised mice. Matrigel implanted
alone or Matrigel with normal neonatal HdLECs or MSCs served as controls. The proposed
progenitor cells of infantile hemangioma, HemSCs (hemangioma stem cells), were also
Fig 5. LMPCs differentiated into abnormal lymphatic endothelial cells. LMPCs isolated frommixed
cervicofacial (Mixed CF) LM, macrocystic mesenteric (Macro Mes) LM and a generalized lymphatic anomaly
(GLA) were maintained in growth media (control) or lymphatic endothelial differentiation (LEC Diff) media for
two weeks. (A) CD31/VE-cadherin and (B) LYVE1/podoplanin staining. Scale bars: 50μm. (C) VEGFR-1,
VEGFR-2, VE-cadherin, Prox1, Podoplanin, LYVE1, and VEGFR-3 qRT-PCR of RNA isolated from LMPCs
maintained in growth or LEC differentiation (LEC Diff) media. Data normalized to β-actin qRT-PCR and
represented as mean ± s.e.m. * p< 0.05, ** p< 0.005, *** p< 0.0005.
doi:10.1371/journal.pone.0117352.g005
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assessed in the xenograft model. Implants were removed at 3 and 5 weeks, and sections were
H&E stained. Similar to patient LM tissue, large channels and ectatic lymphatic vessels were
observed in the LMPC implants (Fig. 6A). In both LMPC implants and LM patient tissues,
sloughing of the endothelium into the dilated lymphatic channels was observed. Unlike
LMPCs isolated from lymphatic anomalies, HemSCs from a blood vessel anomaly, infantile
hemangioma [11], did not develop dilated channels. Aberrant vessels were not observed in
Matrigel implants, or implants that contained MSC or HdLEC.
LMPC and control implants were immunostained for GFP to identify host-derived cells,
and human-specific podoplanin to visualize LM-cell derived lymphatic vessels. In HdLEC im-
plants, lymphatic vessels stained strongly for podoplanin and were observed to lie between
host-derived GFP+ adipocytes (Fig. 6B). In LMPC implants, the cells lining the dilated channels
Fig 6. LMPC recapitulated the LM phenotype in a mousemodel. LMPCs isolated frommixed
cervicofacial (Mixed CF), macrocystic cervicofacial (Macro CF) and mixed mesenteric (Mixed Mes) LM were
suspended in Matrigel and implanted into GFP-expressing immunocompromised mice. Matrigel alone,
mesenchymal stem cells (MSCs), normal human dermal lymphatic endothelial cells (HdLEC) and
hemangioma stem cells (HemSC) served as controls. (A) Hematoxylin and eosin (H&E) staining of xenograft
sections. (B) GFP (host cell) and podoplanin staining of xenograft sections. Scale bars: 50μm. lymphatic
channel (lc)
doi:10.1371/journal.pone.0117352.g006
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stained positive for podoplanin and negative for GFP, demonstrating that the abnormal lym-
phatic vessels were derived from the LMPCs (Fig. 6B). Podoplanin expression was not observed
in MSC or Matrigel controls (Fig. VI in S2 File).
To further characterize the podoplanin+ vessels in the LMPC implants, patient-matched
CD133+ LMPC and CD133− LMEC implants were stained for additional lymphatic endothelial
specific proteins, LYVE1, Prox1 and VEGFR-3. Similar to patient LM tissues, expression of
LYVE1 was variable in the cells lining the dilated lymphatic vessels of LMPC and LMEC im-
plants (Fig. 7A). The aberrant lymphatic vessels in LMPC and LMEC implants also stained
positive for Prox1 and VEGFR-3 (Figs. 7B, 8). The expression levels and patterns of podopla-
nin, LYVE1, Prox1 and VEGFR-3 were similar in the dilated vessels of LMPC and LMEC im-
plants. In the xenograft model, LMPCs differentiated into LMECs and recapitulated the
LM phenotype.
Discussion
We have identified and isolated lymphatic malformation progenitor cells from LM patients.
CD133+/podoplanin+ LMPCs were observed in the abnormal lymphatic endothelium and ad-
jacent parenchyma of LM tissues, independent of anatomic location (cervicofacial, mesenteric,
thoracic, subcutaneous, diffuse) or sub-type (macrocystic, microcystic, mixed macro/microcys-
tic, GLA), suggesting that LMPCs are common to lymphatic anomalies. Isolated CD133+
LMPCs expressed multiple markers of stem cells (NANOG, Oct4), endothelial cell precursors
(CD34, CD90, CD146, c-Kit, VEGFR-2) and lymphatic endothelial proteins (podoplanin,
VEGFR-3). In vitro, LMPCs were multipotent, and could be induced into adipocytes, osteo-
cytes, smooth muscle cells and LECs. Characterization of CD133− LM cells isolated from LM
fluids indicated these cells were lymphatic malformation endothelial cells. Relative to CD133+
LMPCs, CD133− LMECs had decreased or absent expression of stem cell genes (NANOG,
Oct4, c-Kit), maintained the expression of the endothelial precursor markers (CD90, CD146,
VEGFR-2), and exhibited increased expression of the endothelial/lymphatic endothelial mark-
ers (VE-cadherin, CD31, podoplanin, VEGFR-3, Prox1). In addition, CD133− LMECs were
not multipotent. Finally, CD133+ LMPC xenografts developed abnormal lymphatic vessels that
expressed podoplanin, LYVE1, Prox1 and VEGFR-3, similar to patterns observed in LM pa-
tient tissues and CD133− LMEC xenografts. Taken together, this data provides strong evidence
that LMPCs are the cell type of origin in LMs.
In humans, CD133+/CD34+/VEGFR-3+ cells isolated from the fetal liver have been shown
to differentiate into LECs in vitro [21]. These CD133+/CD34+/VEGFR-3+ LEC progenitors
were enriched in the fetal liver, but also present in fetal cord blood. In adult mice, bone mar-
row-derived progenitors have been shown to incorporate into the lymphatic endothelium in
mouse models of inflammation-induced lymphangiogenesis in the cornea, wound healing, and
tumor xenografts [14, 22–24]. These bone marrow-derived LEC progenitors have been de-
scribed as either CD34+/VEGFR-2+/VEGFR-3+ [24] or podoplanin+/c-Kit+/VEGFR-2+/
CD11b+ [14]. The CD133+ cells we isolated from LM specimens expressed multiple markers of
fetal and adult LEC progenitors, including CD133, CD34, podoplanin, c-Kit, VEGFR-2 and
VEGFR-3. LMPCs did not express high levels of CD11b, but did expressed CD90, CD146 and
NG2. Bone marrow MSCs have been described to be express CD90, CD146, and NG2 [25–28],
while neuronal progenitors also express CD90 and NG2 [26, 29, 30]. Taken together, these
data suggest that LMPCs are abnormal lymphatic endothelial progenitors that likely arise from
the bone marrow or a neuronal progenitor. Alternatively, LMPCs may be derived from a multi-
potent pericyte progenitor [31, 32]. Similar to LMPCs, pericytes express CD90, CD146 and
NG2 and can be induced to differentiate down the bone, fat, and cartilage pathways [33].
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However, pericytes are defined as negative for the endothelial precursor marker, CD34, which
is expressed by LMPCs [32, 33]. Thus, the cell-type or organ of origin for LMPCs
remains undefined.
Podoplanin+/VEGFR-3+/CD31+ LECs isolated from LM tissues have previously been
shown to develop abnormal podoplanin+/LYVE1low lymphatics in Matrigel implants in mice
[34]. We demonstrate that CD133+ LMPCs that are podoplanin+/VEGFR-3+/CD31−, as well as
CD133− LMECs that are podoplanin+/VEGFR-3+/CD31+, develop ectatic aberrant lymphatics
that phenocopy the lymphatic vessel morphology in LM tissues. Like LMEC implants and LM
tissues, lymphatic vessels in LMPC implants express podoplanin, VEGFR-3, and Prox1, and
Fig 7. Patient-matched LMPC and LMEC implants expressed the lymphatic proteins, LYVE1 and
VEGFR-3. CD133+ LMPCs and CD133- LMECs isolated from a microcystic subcutaneous LM were
suspended in Matrigel and implanted in immunocompromised mice. Staining of implants was compared to
microcystic subcutaneous LM patient tissue (Micro LM tissue). (A) Podoplanin and LYVE1 and (B)
podoplanin and VEGFR-3 staining. Scale bars: 50μm.
doi:10.1371/journal.pone.0117352.g007
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discontinuous and low levels of LYVE1. Thus, we propose that CD133+ LMPCs contribute to
the pathological lymphatic vessel development of LMs.
The abnormal dilated lymphatic vessels in LM patients and LMPC implants shared some
similarities with the immature lymphatic vessels in the neonatal dermis. Unlike mature lym-
phatics in uninvolved tissues, the immature lymphatic vessels in neonatal tissue expressed high
levels of CD133, similar to LM vessels. In contrast, LYVE1 expression was discontinuous and
reduced in the aberrant lymphatic vessels in LM tissues and LMPC or LMEC xenografts. Low-
level LYVE1 expression was also observed in LMECs isolated from patients or differentiated
from LMPCs in vitro. LYVE1 function in the lymphatic vasculature is poorly understood, and
embryonic lymphatic vessel growth appears unaffected in LYVE1 knockout mice [35]. Howev-
er, closer analysis of the vessel morphology of adult mice has demonstrated that LYVE1 knock-
out mice have distended or disorganized lymphatics in the intestines and liver [36]. LYVE1
was recently shown to bind FGF-2 and function to suppress FGF-2-induced LEC proliferation,
migration, and invasion [37]. Thus, the defect in LYVE1 expressions observed in LMECs may
contribute to the abnormal dilated lymphatic phenotype observed in LM lesions.
Unlike HdLECs that formed uniform and nondilated lymphatics in the mouse model,
LMPCs differentiated into LMECs that formed ectatic lymphatic vessels, with sloughing of the
Fig 8. Patient-matched LMPC and LMEC implants expressed the lymphatic endothelial master
regulator, Prox1. CD133+ LMPCs and CD133− LMECs isolated from a microcystic subcutaneous LM were
suspended in Matrigel and implanted in immunocompromised mice. Podoplanin and Prox1 staining of
implants was compared to microcystic subcutaneous LM patient tissue (Micro LM tissues). Arrows mark
Prox1 positive nuclei. Boxed areas enlarged below. Scale bars: 50μm.
doi:10.1371/journal.pone.0117352.g008
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abnormal lymphatic endothelium into vessel lumens. This sloughing may be due to defective
LEC-LEC interactions. Consistent with this notion, LMECs were abundant in the LM patient
fluid aspirates. We posit that this LMEC shedding may be secondary to defects in VE-cadherin
function. Although VE-cadherin was expressed in LMECs or LMEC differentiated from
LMPCs, it was often not present in adherens junctions. This improper localization of VE-
cadherin may be secondary to defects in other components of the adherens junctions, such as
α- or β-catenin.
Patients with well-circumscribed macrocystic LMs can often be effectively treated by surgi-
cal excision of the affected area, or by sclerotherapy. However, a majority of LMs present with
wholly or partially microcystic or diffuse disease that responds poorly to surgery and sclero-
therapy, with recurrence observed in 22–59% of LM patients [5, 6]. The presence of lymphatic
progenitor cells, after surgical or ablative chemical treatment, may explain this high rate of re-
currence. Thus, therapeutic interventions that target both the abnormal lymphatic endotheli-
um and the progenitor cell population in LMs may be required for clinical efficacy. We
propose that identification of LMPCs and the development of a mouse LMmodel that we de-
scribe here will provide critical tools to allow for development of treatment options for patients
with LMs.
Supporting Information
S1 File. File includes Tables I-III. Table I: Summary of LM tissues and cells analyzed. Table II:
Antibodies. Table III: Quantitative RT-PCR Primers.
(PDF)
S2 File. File includes Figs. I-VI. Fig. I: LM tissues histology. (A) H&E staining of patient-
matched uninvolved and mixed cervicofacial (Mixed CF) LM tissues. (B) H&E staining of neo-
natal control tissue, Mixed CF LM or Gorham’s tissues. Arrowheads mark abnormal lymphatic
vessels. Scale bars: 50μm. lymphatic channel (lc). Fig. II: Analysis of progenitor and stem cell
markers in CD133+ and CD133− LM cells. (A) CD11b and podoplanin FACS of patient-
matched CD133+ and CD133− LM cells isolated from microcystic mesenteric (Micro Mes) LM,
microcystic subcutaneous (Micro SC) LM and general lymphatic anomaly (GLA) specimens.
(B) NANOG, Oct4 and c-Kit qRT-PCR of RNA isolated from patient-matched CD133+ and
CD133− LM cells isolated from a macrocystic mesenteric LM. Data normalized to β-actin qRT-
PCR and represented as mean ± s.e.m.  p< 0.01,  p< 0.0005. Fig. III: LMPCs and not
LMECs were multipotent. (A) Oil Red O staining of MSCs, LMPCs isolated from mixed cervi-
cofacial (Mixed CF) LM and patient-matched LMPCs and LMECs isolated from macrocystic
mesenteric (Macro Mes) LM after 2 weeks in adipogenic media. (B) Alkaline phosphatase
staining of MSC, LMPCs isolated fromMixed CF LM and patient matched LMPCs and
LMECs isolated fromMacro Mes LM after 2 weeks in osteogenic media. Scale bars: 50μm.
Fig. IV: LMPCs expressed NG2. (A) NG2 and CD133 staining of mixed cervicofacial (Mixed
CF) and microcystic mesenteric (Micro Mes) LM tissues. White arrowheads mark abnormal
lymphatic vessels. (B) NG2 staining of CD133+ LM cells isolated fromMixed CF LM, Micro
Mes LM tissues and generalized lymphatic anomaly (GLA) specimens. (C) NG2 staining of pa-
tient-matched CD133+ LMPCs and CD133− LMECs isolated from macrocystic mesenteric
(Macro Mes) LM and GLA. Scale bars: 50μm. lymphatic channel (lc). Fig. V: CD34+ or podo-
planin+ LMPCs were multipotent. LMPCs isolated from a microcystic subcutaneous were
sorted for CD34 or podoplanin positivity and induced to differentiate into fat, bone, VSMCs
and LECs. (A) Oil Red O staining of CD34+ or podoplanin+ LMPCs after 2 weeks in growth
media (control) or adipogenic media. (B) Alkaline phosphatase (Alk Phos) staining of CD34+
or podoplanin+ LMPCs after 2 weeks in growth media (control) or osteogenic media. (C)
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Alpha smooth muscle actin (αSMA) staining of CD34+ or podoplanin+ LMPCs after 2 weeks
in growth media (control) or mural cell differentiation (Diff) media. (D) Podoplanin and
LYVE1 staining of CD34+ or podoplanin+ LMPCs after 2 weeks in growth media (control) or
LEC differentiation (Diff) media. Scale bars: 50μm. Fig. VI: Analysis of control implants. Matri-
gel alone or MSCs suspended in Matrigel was implanted into GFP-expressing immunocom-
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